On July 21, 2025, ZimVie (ZIMV) issued a press release announcing ZimVie’s entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED for $19.00 in cash per share. The transaction is expected to close by year-end 2025, subject to the satisfaction of customary closing conditions, including approval by ZimVie’s stockholders and receipt of applicable regulatory approvals. Upon completion of the transaction, ZimVie will become a privately held company and shares of ZimVie common stock will no longer be listed or publicly traded on the NASDAQ stock exchange. Due to the pending transaction, ZimVie will not host a conference call for the second quarter and ZimVie is withdrawing fiscal 2025 guidance. ZimVie’s previous financial guidance should not be relied upon.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZIMV:
- ZimVie announces exclusive distribution agreement with Osstem Implant in China
- ZimVie upgraded to Equal Weight from Underweight at Barclays
- ZimVie Stock (ZIMV) Rockets 120% on ARCHIMED Deal
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Hold Rating Maintained on ZimVie Inc Amid Acquisition by ARCHIMED